Advanced Biomed Inc. 8-K

What Happened
Advanced Biomed Inc. announced on June 30, 2026 that it entered into a Share Purchase Agreement to sell 100% of the issued and outstanding shares of its wholly‑owned Taiwan subsidiary (Advanced Biomed Inc. (Taiwan)) to an unrelated third party for an aggregate purchase price of US$490,000. The transaction is expected to close within three months of the June 30, 2026 agreement date.

Key Details

• Seller: Advanced Biomed Inc.; Target: Advanced Biomed Inc. (Taiwan), a wholly‑owned subsidiary.
• Purchase price: US$490,000 (aggregate).
• Date of agreement: June 30, 2026; expected closing: within three (3) months of that date.
• The Taiwan subsidiary performs the company’s biomedical R&D, including the A+PerfusC integrated perfusion 3D cell culture platform. After the disposition, Advanced Biomed will continue other businesses, including AI‑focused operations through Acellent Technologies (Hong Kong) Co. Limited.

Why It Matters
This is a material divestiture of the company’s biomedical R&D arm and a concrete step in reshaping Advanced Biomed’s operations. The sale will provide roughly US$490,000 in proceeds if completed, and will remove the Taiwan subsidiary’s assets and activities (including A+PerfusC R&D) from the company’s consolidated operations. Investors should note the transaction is subject to closing conditions and is not final until the parties close; the company says it will continue its remaining businesses, notably its AI‑focused operations.